Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F21%3A00123377" target="_blank" >RIV/00216224:14740/21:00123377 - isvavai.cz</a>
Result on the web
<a href="https://www.mdpi.com/1422-0067/22/11/5536" target="_blank" >https://www.mdpi.com/1422-0067/22/11/5536</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/ijms22115536" target="_blank" >10.3390/ijms22115536</a>

Result language
angličtina
Original language name
Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia
Original language description
Chimeric antigen receptor (CAR) T-cell therapy has already achieved remarkable remissions in some difficult-to-treat patients with B-cell malignancies. Although the clinical experience in chronic lymphocytic leukemia (CLL) patients is limited, the proportion of remissions reached in this disease is clearly the lowest from the spectrum of B-cell tumors. In this review, we discuss the antigenic targets exploited in CLL CAR-T therapy, the determinants of favorable responses, as well as the mechanisms of treatment failure specific to this disease.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology

Project
<a href="/en/project/LQ1601" target="_blank" >LQ1601: CEITEC 2020</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)